Sentien Biotechnologies, Inc., a Medford, MA-based regenerative medicine company developing cell based therapies for acute organ failure, raised a Series A funding round of undisclosed amount.
The investment was led by Boehringer Ingelheim Venture Fund USA, Inc. and Portage Biotech Inc. (Canadian Securities Exchange: PBT.U, OTC Markets : PTGEF).
The company intends to use the funds to conduct a planned Phase I study of their lead product, the Sentinel™, a cell-containing dialysis device for the treatment of Acute Kidney Injury (AKI). In conjunction with the funding, Dr. Martin Heidecker, Managing Director at BIVF, and Dr. Greg Bailey, Chairman of Portage, will be joining Sentien’s Board of Directors.
Led by Brian Miller, CEO, Sentien is a preclinical stage regenerative medicine company that is developing cell based therapies for critical care. Their lead product is being developed to treat severe Acute Kidney Injury, (AKI), the sudden loss of kidney function that can occur after cardiac surgery. Sentien has received different SBIR awards from the U.S. National Institutes of Health (NIH), including a $3M Phase IIB grant to advance the technology into a Phase I clinical trial.